This trial is no longer available!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Erythrocytosis, Familial, 2
Phase
-
The phase for this study is not defined.
Show me locations

The purpose

Chuvash polycythemia (CP) is a rare form of congenital polycythemia caused by mutations in the VHL gene. Currently, there are no therapies that have proven effective for CP. Recent studies have demonstrated that VHL (von Hippel-Lindau tumor suppressor) regulates the activity of JAK2 (Janus kinase 2). In mouse models, inhibition of JAK2 reverses the CP phenotype. Therefore, the investigators hypothesize that JAK2 inhibition may have significant clinical benefits for CP patients.

Provided treatments

  • Drug: Ruxolitinib
Tris trial is registered with FDA with number: NCT01730755. The sponsor of the trial is Washington University School of Medicine and it is looking for 0 volunteers for the current phase.
Official trial title:
Ruxolitinib for Chuvash Polycythemia